QuidelOrtho Corp

QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QuidelOrtho Corp reports strong Q4 earnings, eyes growth opportunities

QuidelOrtho's Q4 performance reflects robust revenue growth and margin stability, driven by key diagnostic segments.
While facing challenges in certain units and regions, the company is focused on resolving supply chain issues and maintaining market leadership.
With a positive outlook for 2023, driven by new product launches and market expansion, QuidelOrtho aims for sustained growth and profitability.

QuidelOrtho Corp (QDEL) reports strong Q1 earnings, eyes global expansion

QuidelOrtho's Q1 2023 performance was strong, driven by non-respiratory revenue growth and exceeding expectations in Point-of-Care business. The company is confident in its growth drivers and ability to launch Savanna ahead of the next respiratory season. Challenges include revenue declines in certain segments and margin impacts.

QuidelOrtho Corp reports strong Q2 earnings and eyes growth opportunities

QuidelOrtho Corp's Q2 performance was robust, with strong revenue, growth in key segments, and increased cost synergies. While facing challenges in certain business areas, the company is optimistic about opportunities for growth, especially in the Point-of-Care and molecular diagnostics markets.

QuidelOrtho Corp reports strong Q3 earnings and eyes China growth

QuidelOrtho Corp's Q3 2023 earnings call highlighted strong financial performance, diversified revenue streams, and a focus on innovation and growth strategies.
The company's emphasis on respiratory products, cost efficiencies, and market expansion in China and the U.S. positions it for continued success and value creation.
Challenges include managing working capital, navigating pricing dynamics, and sustaining growth post-COVID-19, while opportunities lie in product innovation, market expansion, and strategic capital deployment.
Overall, QuidelOrtho Corp's performance reflects resilience, adaptability, and a strategic approach to driving growth and profitability in the healthcare diagnostics sector.

QuidelOrtho Corp reports 2023 earnings, eyes growth opportunities in 2024

QuidelOrtho Corp navigated challenges in 2023 due to lower respiratory season but remains focused on growth and efficiency.
Strategic initiatives include transitioning out of donor screening, investing in immuno hematology, and cost reduction measures.
Confidence in achieving financial goals by 2025, with a strong focus on business efficiency and revenue expansion opportunities.
2024 revenue guidance reflects a strategic shift towards nonrespiratory revenue growth and cost reduction for improved performance.

QuidelOrtho Corp reports revenue growth and cost savings in Q1

QuidelOrtho's Q1 2024 performance showed revenue growth and cost-saving initiatives, despite a significant goodwill impairment charge.
The company's strengths lie in strong revenue growth in key regions, diverse product portfolio, and strategic cost reductions.
Challenges include suspended guidance, lack of flu numbers update, and ongoing head count reductions, while opportunities exist in customer agreements and new product trials.

QuidelOrtho Corp reports solid Q2 results, eyes margin expansion

QuidelOrtho Corp (QDEL) is on track with revenue and EBITDA targets, focusing on margin expansion.
While facing challenges in certain revenue segments, the company is driving cost efficiencies and new product launches.
Opportunities lie in healthcare segment growth and achieving targeted margin expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2021. First Quarter 2021 Highlights Total revenue increased 115% to $375.3 million, from $174.7 million in the first quarter of 2020. Total sales of COVID-19 products were $280.3 million, as compared to $1.0 million in the first quarter of 2020. Tot

Quidel Reports First Quarter 2021 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today a retail collaboration with Walgreens to make Quidel's non-prescription QuickVue® At-Home OTC COVID-19 Test available to consumers at 7,600 Walgreens locations across the United States and Puerto Rico. The shelf-stable packages, each containing two of the self-administered rapid antige

Quidel Forms Retail Collaboration With Walgreens for Over-the-Counter Sale of QuickVue® At-Home OTC COVID-19 Tests

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the BofA Securities 2021 Health Care Conference, to be held virtually on Thursday, May 13, 2021. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present that day at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) in

Quidel to Present Virtually at the BofA Securities 2021 Health Care Conference

iRhythm Technologies

Meten Holding Group Ltd.

Splunk

An important indicator for investors to consider could be a stock's 52-week trading range, the range showing the lowest and highest price a particular stock traded over the trailing year. Finding stocks trading near 52-week lows can be a strategy to find fallen companies that could still have fundamentals, a story in place and could be rebound candidates.

4 Stocks At 52-Week Lows That Could Bounce

Diagnostic test manufacturer Quidel's stock has slumped for good reason. Even so, this might be a good time to buy it.

A Hypergrowth Company With a Crashing Stock Price

Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quidel (QDEL) Earnings Expected to Grow: Should You Buy?

COVID-19 contributed to a 126% increase in revenues through the approval received for diagnostic kits for emergency use. Excluding that, Quidel remains a strong competitor within the high growth diagnostics market with a focus on a wider range of products.

Quidel: More Than Just A Pandemic Stock

Teladoc

Market sentiment about these formerly hot stocks has soured, but there are positive catalysts for both on the horizon.

2 Great Healthcare Stocks to Buy on Sale Right Now

SAN DIEGO--(BUSINESS WIRE)-- #LymeDisease--May 5 webinar to help physicians differentiate between Lyme disease and COVID-19 is the latest in an ongoing series sponsored by Quidel.

Teaching Doctors Nationwide How to Recognize and Differentiate Between Lyme Disease, COVID-19 and the Flu in Quidel-Hosted May 5 Webinar

The stock price of Quidel Corporation, a clinical genetic testing company, has seen a 10% drop in just five trading sessions. The decline was driven primarily due to the company's preliminary report for Q1 with sales estimated to be between $374 million to $376 million, which is well short.

Can Quidel Stock Rebound After A 10% Drop Last Week?

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal first quarter 2021 financial results after market close on Thursday, May 6, 2021. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Easter

Quidel to Hold Fiscal First Quarter 2021 Financial Results Conference Call on May 6th, 2021

The stock price of Quidel Corporation (NASDAQ: QDEL) fell by over 14% pre-market. This is why it happened.

QDEL Stock: Over 14% Decrease Pre-Market Explanation

Quidel Corporation (NASDAQ: QDEL) shares witnessed a drop after announcing lower-than-expected preliminary results for Q1 of 2021 after the bell on Thursday. The company expects Q1 revenues in the range of $374 million to $376 million, up 114% Y/Y, but far below the consensus estimate of $466 million.

Quidel Shares Plunge On Lower Than Expected Q1 Outlook

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has completed a distribution and fulfillment agreement with McKesson Corporation, a global leader in healthcare supply chain management solutions and retail pharmacy, to expedite consumer access to Quidel's non-prescription QuickVue® At-Home OTC COVID-19 Test. The agreement wit

Quidel Signs Retail Distribution Agreement to Increase Access to At-Home COVID-19 Testing

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today preliminary results for the first quarter of 2021. The Company expects revenues in the first quarter of 2021 to be in the range of $374 million to $376 million, up approximately 114% from $174.7 million in the prior year quarter. In the quarter, Quidel shipped nearly 15 million SARS tests, whi

Quidel Announces Preliminary Revenue for First Quarter 2021

Abbott Labs

Becton, Dickinson and Co.

Fulgent Genetics

Less COVID-19 testing means less revenue for some companies.

Which Stocks Are the Biggest Losers From Sinking COVID Testing Rates?

Quidel (QDEL) closed at $129.24 in the latest trading session, marking a -0.28% move from the prior day.

Quidel (QDEL) Stock Moves -0.28%: What You Should Know

QDEL has favorable valuation relative to the industry and its peers, which places it at a favorable purchase given a long-term horizon. QDEL is a company that, due to its positioning in an industry, was able to profit largely from producing COVID-19 tests at the onset of the pandemic.

Quidel: Growth Beyond COVID-19

SAN DIEGO--(BUSINESS WIRE)-- #bayarealymefoundation--Quidel Corporation partners with the Bay Area Lyme Foundation to help heighten public awareness to Lyme disease.

Quidel Corporation Partners With the Bay Area Lyme Foundation to Heighten Public Awareness of Lyme Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Quidel Taps ICS to Collaborate on Next-Gen Multiplex Molecular Diagnostic Instruments for SARS-CoV-2/COVID Pathogen Detection

Quidel Taps ICS to Collaborate on Next-Gen Multiplex Molecular Diagnostic Instruments for SARS-CoV-2/COVID Pathogen Detection

SAN DIEGO--(BUSINESS WIRE)-- #Lyme--Quidel, the nation's leading developer of rapid Lyme disease testing, cautions Americans to be vigilant, take precautions and get tested if in doubt.

Start of Lyme Disease Season Provides Heightened Risks for Americans Wanting to Go Outdoors After a Year of COVID-19 Restrictions

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), allowing the company to market its Sofia® SARS Antigen FIA for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 from anterior nares swab specimens di

Quidel's Sofia® SARS Antigen Test Receives Emergency Use Authorization for Screening Use With Serial Testing

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it is partnering with the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) on an innovative community health initiative called “Say Yes! COVID Test” in Pitt County, North Carolina, and coming soon to Chattanooga/Hamilton County, Tennesse

Quidel Supports New NIH, CDC Public Health Initiative for At-home COVID-19 Testing

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), allowing the company to market its new QuickVue® At-Home OTC COVID-19 Test for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 from individuals with

Quidel's QuickVue® At-Home OTC COVID-19 Test Receives Emergency Use Authorization for Screening Use With Serial Testing

With everyone tired of Covid-19 lockdowns and protocols, it's hard to see QDEL stock as a confident contrarian trade. The post Covid Fatigue Threatens to Derail Once Relevant Quidel appeared first on InvestorPlace.

News for QuidelOrtho Corp Stock (QDEL)